Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Show more

Location: 1065 East Hillsdale Boulevard, Foster City, CA, 94404, United States | Website: https://www.ternspharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.37B

52 Wk Range

$1.86 - $28.49

Previous Close

$26.11

Open

$25.99

Volume

2,486,562

Day Range

$25.31 - $26.51

Enterprise Value

2.076B

Cash

295.6M

Avg Qtr Burn

-19.42M

Insider Ownership

0.29%

Institutional Own.

98.52%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TERN-701 Details Chronic myeloid leukemia (CML)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-601 (GLP-1R agonists) Details Obesity	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-501 (THR-B Agonist) +/- TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.